http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100921918-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100921918-B1 |
| titleOfInvention | Treatment method using gene therapy of lung cancer |
| abstract | The present invention relates to a therapeutic method that enables gene therapy of lung cancer by inhibiting cancer metastasis while attacking a cancer tumor. Specifically, CTMP (carboxyl terminal modulator protein) is used as an agent, and a lentivirus is used as a gene carrier. We evaluated the efficiency of lentiviral vector-mediated CTCT and the potential effects of Akt1 on Akt-related signals and cell cycle regulation.Lentivirus-CTMP was delivered to K- ras- depleted lung cancer mice by a nasal-inhaled system. The delivered lentivirus not only significantly inhibited lung tumor development, but also confirmed that aerosol delivery of the lentivirus vector mediated-CTMP could be used in combination with invasive in vivo gene therapy.n n n n Lung cancer, CTMP, Akt, lentivirus, aerosol |
| priorityDate | 2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 347.